Suchergebnisse
10
Alles
Such-Filter
Tag
dermatology
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
26. März 2025 16:01 ET
|
Journey Medical Corporation
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended...
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
25. März 2025 02:30 ET
|
Alumis Inc.
Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
24. März 2025 08:30 ET
|
Journey Medical Corporation
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...
Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219
20. März 2025 07:00 ET
|
Sitryx Therapeutics
Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease...
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
19. März 2025 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Cytrellis Secures Health Canada and Saudi Food and Drug Authority Approval for ellacor® with Micro-Coring® Technology
18. März 2025 08:05 ET
|
Cytrellis Biosystems
Cytrellis Biosystems has received approval to commercialize its groundbreaking ellacor® with Micro-Coring® technology in Canada and Saudi Arabia.
Study Reveals Lack of Physician Oversight in Missouri Medical Spas, Raising Patient Safety Concerns from ASDSA
17. März 2025 07:00 ET
|
American Society for Dermatologic Surgery Association
Schaumburg, Ill., March 17, 2025 (GLOBE NEWSWIRE) -- A new study published in the January 2025 issue of Dermatologic Surgery – the official scientific journal of the American Society for...
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
13. März 2025 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review...
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
12. März 2025 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and...
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
08. März 2025 13:00 ET
|
Regeneron Pharmaceuticals, Inc.
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly...